The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-10. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== History == Dihydroergotamine was synthesized by Albert Hofmann and Werner Stoll at Sandoz in 1943. It was first described in the scientific literature that same year. Dihydroergotamine was first approved for medical use under the brand name D.H.E. 45 in 1946. Dihydroergotamine is derived from ergot, a fungus that grows on rye and other grains.
In other places, such as Australia, suvorexant is a prescription-only medicine and is not a controlled drug. Suvorexant is not available in generic formulations. Besides suvorexant, other orexin receptor antagonists like lemborexant and daridorexant have also been introduced.
It was this late version (not the European ROM) that served as the basis for the port on the PC. The game was one of the first games to be released under the Disney Interactive label. By the 1996 holiday shopping season, the CD-based PlayStation and Saturn consoles had achieved a significant presence in the market, making third party publishers reluctant to spend money on expensive cartridges for consoles such as the Super NES. Because of this, Nintendo (which owned the factory where Super NES cartridges were made and thus could manufacture them more cheaply than third parties could) licensed the game from Disney Interactive and published it in North America and Europe. The game premiered for the North American market at Walt Disney World in September 1996. Three Maui Mallard kiosks were prepared in the Disney Interactive exhibit at the Innoventions plaza of EPCOT. Visitors could play the full game for an unlimited period of time and interact with Attractions Hosts and Hostesses who were available to play against them and share tips and tricks. According to composer Patrick Collins, Donald Duck's name was dropped from the North American release because the marketing team felt that "Donald Duck just isn't hip in the United States like he is in Europe".
Sources: en.wikipedia.org
All three ethanolamines are produced in the process, while ammonia and part of methylamine are recycled. The final products are separated by vacuum distillation. Hydroxyalkylamines are produced in a similar process:
== Controversy on acidity == Recent research has challenged these proposed ranges, finding that healthy human skin naturally tends to return to acidity levels below 5.0 when left untouched by skincare products or water for extended periods. An ideal pH value of 4.7 has been identified, with some individuals showing levels as low as 4.3. Subjects with a skin pH below 5.0 exhibited significantly less scaling, higher hydration levels, and better skin flora presence compared to those with higher pH levels, suggesting better overall skin condition. The acidic surface pH is crucial for the growth conditions of resident skin microbiota, which play a vital role in maintaining skin health. Human skin and its microbiota have a mutually beneficial symbiotic relationship, with the skin providing an optimal environment for resident microbiota while the microbiota help reinforce the skin's immunity by preventing colonization by harmful pathogens and contributing to skin acidification. Skin care products that lower skin pH to 4.0–4.5 help maintain resident microbiota on the skin, whereas alkaline personal care products promote their dispersal.
United States Minor Outlying Islands - Special permits required for Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Atoll, Palmyra Atoll and Wake Island. Venezuela. Margarita Island - Visa not required. All visitors are fingerprinted. Vietnam. Phú Quốc - Visa not required for 30 days. Yemen outside Sana'a or Aden - Special permission needed for travel outside Sana'a or Aden. UN Buffer Zone in Cyprus - Access Permit is required for travelling inside the zone, except Civil Use Areas. Korean Demilitarized Zone - Restricted area. UNDOF Zone and Ghajar - Restricted area.
Sources: en.wikipedia.org
However, melting temperature and the overall shape of the melting curve become informative. For amplicons >c.150bp there are often >2 melting peaks, each of which can vary, depending on the DNA template composition. Numerous investigators have been able to successfully eliminate the majority of their sequencing through melt-based scanning, allowing accurate locus-based genotyping of large numbers of individuals. Many investigators have found scanning for mutations using high resolution melting as a viable and practical way to study entire genes.
=== Betaines and similar compounds === The compound trimethylglycine, named as "betaine", contain the same structural motif, a quaternary nitrogen atom with a carboxylate group attached to it via a –CH2– link. All compounds whose structure includes this motif are known as betaines. Betaines do not isomerize because the chemical groups attached to the nitrogen atom are not labile. These compounds may be classed as permanent zwitterions, as isomerisation to a molecule with no electrical charges does not occur, or is very slow. Other examples of permanent zwitterions include phosphatidylcholines, which also contain a quaternary nitrogen atom, but with a negatively-charged phosphate group in place of a carboxylate group; sulfobetaines, which contain a quaternary nitrogen atom and a negatively charged sulfonate group; and pulmonary surfactants such as dipalmitoylphosphatidylcholine. Lauramidopropyl betaine is the major component of cocamidopropyl betaine.
At the meeting to close the deal, one of the bankers recorded, "Michael thought he was President of the Oxford Union again, and entered into a grand oration and bored everyone stiff". In 1971 Heseltine placed his shares in a trust controlled by his ministerial boss Peter Walker and by his solicitor Charles Corman. Haymarket's pretax profits were £453,000 in 1971 and £704,000 in 1972. Haymarket was due to be floated as a public company in the autumn of 1973, although this was cancelled because of the rise in the oil price, which reduced the profitability of the publishing industry. They thus avoided the stock market crash which followed. The company remains privately owned to this day. Heseltine acted as a consultant to Haymarket during his period out of government office between 1974 and 1979. His role was to bring in new publishing ideas. He believed he increased performance, although Robert Heller later recorded that he did very little, for he was too busy as a member of the Shadow Cabinet. He worked from an office at Haymarket, near Regent Street, rather than in the House of Commons. Under the management of Masters and Tindall, Haymarket continued to grow. By 1976 it was making annual profits of round £1.75m. In 1976–1977 Heseltine, Masters, Tindall and the Finance Director David Fraser bought out the consortium's 40% share, using money borrowed from them, giving Heseltine and his family over 50% control of Haymarket. Heseltine had taken out large personal loans both to increase his stake in the company and to buy his country mansion Thenford House.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.